M. Debled
Institut Bergonié(FR)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Estrogen and related hormone effects
Most-Cited Works
- → Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)(2015)242 cited
- → Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database(2021)46 cited
- → 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study(2018)38 cited
- → Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up(2011)31 cited
- → LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer(2021)24 cited
- → Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial(2006)10 cited
- → Celecoxib (Ce) + exemestane (Ex) versus placebo + Ex in post-menopausal (PM) metastatic breast cancer (MBC) patients (pts): A double-blind phase III GINECO study(2006)6 cited
- → Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program(2021)6 cited
- → Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >75 years old with metastatic breast cancer(2008)5 cited